Going Public (Life Sciences): Biotechnology Shares in Germany - Deutsches Aktieninstitut Calls for a "New Equity Culture" (in German)

In an interview with Life Sciences, Dr Christine Bortenlänger talks about the ten recommendations of Deutsches Aktieninstitut for the federal elections and why Germany is not attractive as a financial centre for young biotechnology companies. She advocates making shares a fixed component of old-age provision so that capital-rich pension funds emerge in Germany that also invest in growth companies.

The interview with Dr Christine Bortenlänger appeared in Going Public.